Perforation of an Unsuspected Cecal Granulocytic Sarcoma during Therapy with Granulocyte-Macrophage Colony-Stimulating Factor
- 1 February 1990
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (5) , 337-338
- https://doi.org/10.1056/nejm199002013220517
Abstract
Granulocytemacrophage colony-stimulating factor (rhGM-CSF) has recently entered clinical trials for patients with bone marrow failure.1 , 2 We are participating in a crossover study comparing the relative effectiveness of intravenous as compared with subcutaneous rhGM-CSF (Immunex, Seattle; distributed by Hoechst—Roussel Pharmaceuticals, Somerville, N.J.) in patients with myelodysplastic syndromes. We report here on a patient in whom necrosis and perforation of a granulocytic sarcoma of the cecum developed during therapy with rhGM-CSF.Keywords
This publication has 4 references indexed in Scilit:
- Phase I/II study of recombinant human granulocyte-macrophage colony- stimulating factor in aplastic anemia and myelodysplastic syndromeBlood, 1988
- Human GM-CSF primes neutrophils for enhanced oxidative metabolism in response to the major physiological chemoattractantsBlood, 1987
- Effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukemiaBlood, 1986
- Biosynthetic (recombinant) human granulocyte-macrophage colony- stimulating factor: effect on normal bone marrow and leukemia cell linesBlood, 1986